|
Oregon
DUR Board Newsletter
Vol.
6, No. 2, February 2004
Copyright
2004 Oregon State University All Rights Reserved
Prilosec OTC Offers Exceptional Value for PPI Therapy
By Dean Haxby, Pharm.D. , OSU College of Pharmacy
Prilosec
OTC was approved by the FDA in June 2003 and is the first proton pump
inhibitor (PPI) available in the U.S. for over-the-counter (OTC)
treatment of frequent heartburn (1). While much attention has been focused
on the availability of this product for self-treatment, the another important
benefit is that it provides clinicians with a low-cost option for one
of the most commonly prescribed, and top expenditure drug classes. For
every patient on chronic PPI therapy converted to Prilosec OTC, the savings
would range from approximately $872-$1208 per year. Therefore, prescribing
Prilosec OTC as an alternative to other PPIs is an important opportunity
for clinicians to help stretch the limited resources of the Oregon Health
Plan.
Differences
Between Prilosec and Prilosec OTC
Prescription
(Rx) omeprazole is a capsule formulation containing enteric-coated
granules of omeprazole
base, whereas Prilosec OTC
is a tablet containing
omeprazole magnesium in an enteric-coated multiple-unit pellet system
(MUPS). Prilosec OTC contains 20.6 mg of omeprazole magnesium, which
provides 20mg of omeprazole base. The omeprazole magnesium salt allows
the formulation and manufacture of tablets that are more tamper-resistant
than capsules, which is an important consideration in the OTC setting
(2). While Rx omeprazole (Prilosec) and Prilosec OTC produce nearly
identical blood levels of omeprazole base and equivalent therapeutic
effects, a
pharmacist may not substitute one for the other. Thus it
is important to specify “Prilosec OTC” or “omeprazole
magnesium” on
the prescription.
Role of
Prilosec OTC in Self-treatment
In two pivotal
studies submitted to the FDA, Prilosec OTC once-daily for 14 days was
more effective than placebo
in patients with frequent
heartburn (1). Within 5 days of stopping treatment, there was
no significant difference in symptoms compared to the control group.
It is recommended
that therapy not be used for more than 14 days in any four-month
period without consulting a clinician. Therefore, the role of
self-treatment
is limited.
Role of
Prilosec OTC in Clinician Directed Care
The same
formulation of omeprazole used for Prilosec OTC is available in 31
other countries, commonly
under the brand name Losec
MUPS (2). Losec MUPS carries similar indications in other countries
as Rx Prilosec
in the US. For example, in the United Kingdom, Losec MUPS
is indicated for esophageal reflux disease, duodenal ulcers, gastric
ulcers, NSAID-induced
ulcers, H. pylori eradication, dyspepsia, prophylaxis of
acid
aspiration and Zollinger-Ellison Syndrome (3).
An evidence-based
review of the PPI drug class conducted by the Oregon Evidence-based
Practice Center under the guidance of the PPI Subcommittee
of the Oregon Health Resources Commission concluded there is
no clinical difference among the various PPIs in terms of efficacy or
safety (4).
As the lowest cost option in the PPI class, Prilosec OTC has been added
to the Oregon Practitioner Managed Preferred Drug List (5).
Adverse
Effects
The
adverse effect profile of Prilosec OTC is similar to
other PPIs. This formulation of omeprazole has established
an extensive
safety
profile based on use abroad (6). Prilosec OTC, like the prescription
product, is well tolerated with headache, diarrhea, nausea, abdominal
pain or rash occurring in 1%-5% of patients. Both omeprazole formulations
may increase levels of drugs metabolized by CYP-2C19, such as warfarin
and phenytoin. Drugs requiring acid for absorption (e.g. itraconazole)
also may be affected.
Cost
While
one PPI does not offer a clinical advantage over another, Prilosec
OTC has a dramatic price advantage. Approximately five patients
can be treated with Prilosec OTC for the cost of treating one
patient
with a different PPI. If 90% of the current open-card Medicaid
PPI users
were converted to Prilosec OTC, the state would save over $3,000,000
in one year.
| Generic |
Brand |
Dose |
Annual
Cost $* |
| Omeprazole mag. |
Prilosec
OTC |
20.6
mg qd |
193 |
| Omeprazole |
Generic
(Rx) |
20
mg qd |
1065 |
| Pantoprazole |
Protonix |
40
mg qd |
1065 |
| Rabeprazole |
Aciphex |
20
mg qd |
1309 |
| Esomeprazole |
Nexium |
20
mg or 40 mg qd |
1343 |
| Lansoprazole |
Prevacid |
30
mg qd |
1401 |
* AWP – 15% based on Redbook Update August 2003 or the OHP maximum
allowable cost for generic omeprazole. Administration
The
adult dose of Prilosec OTC is the same as Rx omeprazole,
typically one tablet (20.6 mg) daily. The tablets may be
dispersed in water, juice
or yogurt for patients with difficulty swallowing tablets. Once dispersed,
the drug can be suspended with gentle mixing and the entire mixture
is consumed. Because the pellets themselves are enteric-coated,
they will
not be dissolved in the acidic medium of the stomach. However, it
is important that the tablets not be crushed or chewed which
would compromise
the enter-coating.
Summary
Clinicians
should prescribe Prilosec OTC as the preferred first line
agent for PPI therapy. It offers comparable
clinical performance
as other PPIs at a fraction of the cost.
Reviewers: Michele Koder, Pharm.D. OSU College of Pharmacy; David Labby,
MD, CareOregon; and Marian McDonagh, Pharm.D. OHSU Evidence-based Practice
Center.
References
1. The Medical Letter; 45 (August 4, 2003):61-2
2. Proctor & Gamble Company-Astrazeneca LP. Omeprazole
magnesium tablets, NDA No. 21-229, Advisory committee briefing
document:May 6,2002.
www.fda.gov/ohrms/dockets/ac/02/briefing/3861b1_01_proctorGamble-Zeneca.pdf:
accessed 2/10/2004
3. Summary of product characteristics: Losec MUPS Tablets.
AstraZeneca UK Ltd., 600 Capability Green, Luton, LU1 3LU,
UK
4. Proton Pump Inhibitors Subcommittee Report, update #1, July,
2003.
www.oregonrx.org/OHPPRREPORTS.html : accessed 2/10/2004
5. Oregon health plan drug list.
www.oregonrx.org/oregon_health_plan_drug_list.html : accessed
2/10/2004
6. Shetty D. OTC medical officer's review.
www.fda.gov/ohrms/dockets/ac/02/briefing/3861b1_03_A-actual%20use.pdf:
accessed 2/10/2004
Return
to Newsletter List.
|